Antiplatelet and anticoagulant therapy in patients undergoing percutaneous transluminal coronary angioplasty

Although coronary angioplasty has been in clinical use for only 15 years, continued refinements in technique, instrumentation, and adjunctive therapy have led to high initial success rates despite broader patient selection and the increasing complexity of lesions attempted. Antiplatelet therapy in the form of 80 to 325 mg of aspirin begun before the procedure has been demonstrated to be of benefit in decreasing the acute complication rate associated with PTCA. In the future, this beneficial effect may be augmented by the addition of monoclonal antibody inhibitors to platelet membrane glycoprotein IIB/IIIa, possibly at the expense of a mild-to-moderate increase in bleeding complications. Although routine prolonged antithrombotic therapy has not been useful after uncomplicated angioplasty, there is evidence that antithrombotic therapy with heparin for 1 or more days before angioplasty will benefit patients with unstable angina or evidence of thrombus on angiography. Although patients with thrombus or coronary dissection after the procedure probably also benefit from extended heparin therapy, most trials have specifically excluded these patients from study. More potent and specific antithrombin and antiplatelet agents are currently being investigated in human trials and may further lower acute complication rates. Although platelets, thrombin, and mural thrombosis have all been implicated as factors in restenosis, the process itself remains incompletely understood, and no therapy has been shown to be of benefit in humans. The specific platelet IIb/IIIa inhibitors, hirudin, hirulog, and factor Xa inhibitors have all shown promise in animal models of restenosis, and ongoing or planned trials will define their efficacy in humans.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Although coronary angioplasty has been in clinical use for only 15 years, continued refinements in technique, instrumentation, and adjunctive therapy have led to high initial success rates.

Leech-derived molecules this paper discusses, each with a full profile in the ASH compound registry:

Узнайте, как это исследование связано с клинической практикой

More peer-reviewed studies in Клинические исследования.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
• Reverse Sural Flap Venous Congestion Successfully Managed With Enoxaparin in a Male Patient With a Traumatic Foot Crush Injury: A Case Report — Velasco-Bustamante J et al. (2026)
• Investigation of the therapeutic effects of medicinal leech treatment on lower extremity ischemia-reperfusion injury — Ünal K et al. (2026)
• Efficacy of Medicinal Leech Therapy in Diverse Clinical Applications: A Comprehensive Study from Azerbaijan — Farzali S et al. (2025)
• HIRUDOTHERAPY IN RECONSTRUCTIVE SURGERY: CASE-REPORTS AND REVIEW — Heinz P et al. (2020)
• Hirudotherapy Efficacy and Complications in the Management of Microsurgical Breast Reconstruction: A Systematic Review — Foppiani J et al. (2024)
• Hirudotherapy in Wound Healing — Nair H et al. (2022)

Browse all ASH-analysed research →